Search results for "CD8"

showing 10 items of 682 documents

The janus face of NKT cell function in autoimmunity and infectious diseases

2018

Natural killer T cells (NKT) are a subset of T lymphocytes bridging innate and adaptive immunity. These cells recognize self and microbial glycolipids bound to non-polymorphic and highly conserved CD1d molecules. Three NKT cell subsets, type I, II and NKT-like expressing different antigen receptors (TCR) were described and TCR activation promotes intracellular events leading to specific functional activities. NKT can exhibit different functions depending on the secretion of soluble molecules and the interaction with other cell types. NKT cells act as regulatory cells in the defence against infections but, on the other hand, their effector functions can be involved in the pathogenesis of sev…

0301 basic medicineglycolipidsAutoimmunityReviewAdaptive Immunitymedicine.disease_causeAutoimmunityCatalysiimmunologylcsh:Chemistry0302 clinical medicineT-Lymphocyte Subsetslcsh:QH301-705.5SpectroscopyInnate lymphoid cellhemic and immune systemsComputer Science Applications1707 Computer Vision and Pattern RecognitionGeneral MedicineNKTNatural killer T cellAcquired immune systemComputer Science ApplicationsCell biologyCD1DmicrobesCell typechemical and pharmacologic phenomenaGlycolipidBiologyCD1dCommunicable DiseasesCatalysisInorganic Chemistry03 medical and health sciencesmedicineAnimalsHumansMicrobePhysical and Theoretical ChemistryMolecular BiologyInflammationT-cell receptorOrganic ChemistryModels ImmunologicalAlpha-galactosylceramideAlpha-galactosylceramide; Autoimmunity; CD1d; Glycolipids; Microbes; NKT; Sulfatide; Catalysis; Molecular Biology; Spectroscopy; Computer Science Applications1707 Computer Vision and Pattern Recognition; Physical and Theoretical Chemistry; Organic Chemistry; Inorganic ChemistryImmunity InnateSettore MED/16 - Reumatologia030104 developmental biologylcsh:Biology (General)lcsh:QD1-999biology.proteinNatural Killer T-CellsSulfatideCD8030215 immunology
researchProduct

Reconstitution of T Cell Proliferation under Arginine Limitation: Activated Human T Cells Take Up Citrulline via L-Type Amino Acid Transporter 1 and …

2017

In the tumor microenvironment, arginine is metabolized by arginase-expressing myeloid cells. This arginine depletion profoundly inhibits T cell functions and is crucially involved in tumor-induced immunosuppression. Reconstitution of adaptive immune functions in the context of arginase-mediated tumor immune escape is a promising therapeutic strategy to boost the immunological anti-tumor response. Arginine can be recycled in certain mammalian tissues from citrulline via argininosuccinate in a two-step enzymatic process involving the enzymes argininosuccinate synthase (ASS) and argininosuccinate lyase (ASL). Here we demonstrate that anti-CD3/anti-CD28-activated human primary CD4+ and CD8+ T c…

0301 basic medicinelcsh:Immunologic diseases. AllergyArginineT cellArgininosuccinate synthaseImmunologyarginineamino acid transporter03 medical and health scienceschemistry.chemical_compoundDownregulation and upregulationT cell metabolismmedicineCitrullineExtracellularT lymphocyteImmunology and AllergybiologyMolecular biologyArgininosuccinate lyase030104 developmental biologymedicine.anatomical_structurechemistrycitrullinebiology.proteinlcsh:RC581-607CD8Frontiers in Immunology
researchProduct

HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory

2019

ABSTRACT HPV16 infections are associated with a variety of cancers and there is compelling evidence that the transforming activity of HPV16 critically depends on the expression of the viral oncoproteins E6 and E7. Therapeutic cancer vaccines capable of generating durable and specific immunity against these HPV16 antigens hold great promise to achieve long-term disease control. Here we show in mice that HPV16 E7 RNA-LPX, an intravenously administered cancer vaccine based on immuno-pharmacologically optimized antigen-encoding mRNA, efficiently primes and expands antigen-specific effector and memory CD8+ T cells. HPV-positive TC-1 and C3 tumors of immunized mice are heavily infiltrated with ac…

0301 basic medicinelcsh:Immunologic diseases. AllergyT cellImmunologyhpv16-positive malignancieslcsh:RC254-282t cell memoryhpv 16 rna-lpx03 medical and health sciences0302 clinical medicineImmune systemAntigenImmunology and AllergyCytotoxic T cellMedicineOriginal Researchbusiness.industryCancermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologymedicine.anatomical_structureOncologyImmunization030220 oncology & carcinogenesisCancer researchCancer vaccinebusinesscancer vaccinelcsh:RC581-607CD8e7OncoImmunology
researchProduct

Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response

2019

TLR7 agonists are considered promising drugs for cancer therapy. The currently available compounds are not well tolerated when administered intravenously and therefore are restricted to disease settings amenable for topical application. Here we present the preclinical characterization of SC1, a novel synthetic agonist with exquisite specificity for TLR7. We found that intravenously administered SC1 mediates systemic release of type I interferon, but not of proinflammatory cytokines such as TNFα and IL6, and results in activation of circulating immune cells. Tumors of SC1-treated mice have brisk immune cell infiltrates and are polarized towards a Th1 type signature. Intratumoral CD8(+) T cel…

0301 basic medicinelcsh:Immunologic diseases. Allergycd8+ t cellsImmunologytype i interferonlcsh:RC254-282Proinflammatory cytokinetlr7 ligand03 medical and health sciences0302 clinical medicineImmune systemInterferonmedicineImmunology and AllergyCytotoxic T cellOriginal ResearchToll-like receptorcancer immunotherapybusiness.industryTLR7Acquired immune systemlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchbusinesslcsh:RC581-607CD8medicine.drugOncoImmunology
researchProduct

A non-functional neoepitope specific CD8+ T-cell response induced by tumor derived antigen exposure in vivo

2018

Cancer-associated mutations, mostly single nucleotide variations, can act as neoepitopes and prime targets for effective anti-cancer T-cell immunity. T cells recognizing cancer mutations are critical for the clinical activity of immune checkpoint blockade (ICB) and they are potent vaccine antigens. High frequencies of mutation-specific T cells are rarely spontaneously induced. Hence, therapies that broaden the tumor specific T-cell response are of interest. Here, we analyzed neoepitope-specific CD8+ T-cell responses mounted either spontaneously or after immunotherapy regimens, which induce local tumor inflammation and cell death, in mice bearing tumors of the widely used colon carcinoma cel…

0301 basic medicinelcsh:Immunologic diseases. Allergycd8+ t cellsmedicine.medical_treatmentImmunologyBiologylcsh:RC254-28203 medical and health sciences0302 clinical medicineCancer immunotherapyAntigenmedicineImmunology and AllergyCytotoxic T cellneoepitopescancer immunotherapycd8+ t cell cytotoxicityT-cell receptorImmunotherapyTumor-Derivedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensImmune checkpointt cell priming030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchlcsh:RC581-607CD8OncoImmunology
researchProduct

A liposomal RNA vaccine inducing neoantigen-specific CD4+ T cells augments the antitumor activity of local radiotherapy in mice

2020

Antigen-encoding, lipoplex-formulated RNA (RNA-LPX) enables systemic delivery to lymphoid compartments and selective expression in resident antigen-presenting cells. We report here that the rejection of CT26 tumors, mediated by local radiotherapy (LRT), is further augmented in a CD8+ T cell-dependent manner by an RNA-LPX vaccine that encodes CD4+ T cell-recognized neoantigens (CD4 neoantigen vaccine). Whereas CD8+ T cells induced by LRT alone were primarily directed against the immunodominant gp70 antigen, mice treated with LRT plus the CD4 neoantigen vaccine rejected gp70-negative tumors and were protected from rechallenge with these tumors, indicating a potent poly-antigenic CD8+ T cell r…

0301 basic medicinemedicine.medical_treatmentT cellImmunology03 medical and health sciences0302 clinical medicineAntigenmedicineImmunology and Allergyrna-lpxcd4+ t cellsradiotherapyRC254-282Antitumor activityLiposomeintegumentary systembusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensRNARC581-607Radiation therapy030104 developmental biologymedicine.anatomical_structureOncologyLocal radiotherapy030220 oncology & carcinogenesisCancer researchImmunologic diseases. Allergybusinesscancer vaccinesneoantigensCD8OncoImmunology
researchProduct

Leukemia-associated activating mutation of Flt3 expands dendritic cells and alters T cell responses

2016

Lau et al. show that the FLT3-ITD mutation directly affects dendritic cell development in preleukemic mice, indirectly modulating T cell homeostasis and supporting the expansion of regulatory T cells.

0301 basic medicinemedicine.medical_treatmentT cellT-LymphocytesImmunologyDown-RegulationBiologyCD8-Positive T-LymphocytesArticle03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesGene DuplicationmedicineImmunology and AllergyAnimalsHomeostasisCell LineageProgenitor cellResearch ArticlesCell ProliferationLeukemiaCell growthGene Expression Regulation LeukemicMyeloid leukemiaMembrane Proteinshemic and immune systemsDendritic CellsCell biologyImmunosurveillanceMice Inbred C57BLHaematopoiesis030104 developmental biologyCytokinemedicine.anatomical_structureImmunologyMutationCD8030215 immunologySignal TransductionThe Journal of Experimental Medicine
researchProduct

Tumor-derived immuno-modulators induce overlapping pro-tolerogenic gene expression signatures in human dendritic cells.

2016

Immature dendritic cells (iDCs) and tolerogenic DCs are essential for the induction and maintenance of peripheral tolerance. Tumors produce immuno-modulatory factors which imprint a pro-tolerogenic, maturation-resistant state in DCs. Here we asked for common markers of differentially tolerized human monocyte-derived DC populations. For this, PBMC-derived monocytes were differentiated to DCs in the presence of established immuno-modulators as released by tumors (IL-6, IL-10, TGF-β, glucocorticoid [GC], prostaglandin E2 [PGE2]). Most unstimulated pro-tolerogenic DC populations commonly over-expressed some tolerance-associated markers (ILT-4, IL-10, HO-1) as compared with iDCs. These markers m…

0301 basic medicinemedicine.medical_treatmentT cellT-LymphocytesImmunologyStimulationBiologyLymphocyte ActivationDinoprostone03 medical and health sciences0302 clinical medicineDownregulation and upregulationNeoplasmsmedicineImmune ToleranceImmunology and AllergyHumansImmunologic FactorsProstaglandin E2GlucocorticoidsCells CulturedAntigen PresentationPeripheral toleranceCell DifferentiationGeneral MedicineDendritic CellsInterleukin 10030104 developmental biologyCytokinemedicine.anatomical_structureImmunologyB7-1 AntigenCytokinesCD80Heme Oxygenase-1030215 immunologymedicine.drugHuman immunology
researchProduct

Preproinsulin designer antigens excluded from endoplasmic reticulum suppressed diabetes development in nod mice by dna vaccination

2019

DNA vaccines against autoimmune type 1 diabetes (T1D) contain a nonpredictable risk to induce autoreactive T cell responses rather than a protective immunity. Little is known if (and how) antigen expression and processing requirements favor the induction of autoreactive or protective immune responses by DNA immunization. Here, we analyzed whether structural properties of preproinsulin (ppins) variants and/or subcellular targeting of ppins designer antigens influence the priming of effector CD8+ T cell responses by DNA immunization. Primarily, we used H-2b RIP-B7.1 tg mice, expressing the co-stimulator molecule B7.1 in beta cells, to identify antigens that induce or fail to induce autoreacti…

0301 basic medicinepreproinsulin/proinsulin antigensPreproinsulinlcsh:QH426-470type 1 diabetesMouse ModelsBiologyMajor histocompatibility complexArticleDNA vaccinationDNA vaccines03 medical and health sciences0302 clinical medicineImmune systemAntigenImmunityGeneticsmouse models:Science::Medicine [DRNTU]lcsh:QH573-671Molecular BiologyNOD micelcsh:Cytologylcsh:Geneticsendoplasmic reticulum030104 developmental biology030220 oncology & carcinogenesisImmunologybiology.proteinType 1 DiabetesMolecular MedicineCD8
researchProduct

Gene Therapy With a High-Affinity Single-Chain p53-Specific TCR Mediates Potent Anti-Tumor Response Without Inducing Gvhd In Vivo

2013

Abstract The adoptive transfer of tumor-reactive cells is a promising approach in the treatment of human malignancies, but the challenge of isolating T cells with high-avidity for tumor antigens in each patient has limited its widespread application. Using HLA-A2.1 transgenic mice, we have demonstrated the feasibility of T-cell receptor (TCR) gene transfer into T cells to circumvent self-tolerance to the widely expressed human p53(264-272) tumor-associated antigen and developed approaches to generate high-affinity CD8-independent TCR. However, a safety concern of TCR gene transfer is the risk of pairing between introduced and the naturally expressed endogenous TCR chains, resulting in the g…

Adoptive cell transferCD3Genetic enhancementmedicine.medical_treatmentImmunologyT-cell receptorCell BiologyHematologyImmunotherapyBiologyBiochemistryAntigenHumanized mouseImmunologyCancer researchbiology.proteinmedicineCD8Blood
researchProduct